Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy
- Address
- lock Available on a paid plan
Advanced Liver Cancer Research
The Narodowy Instytut Onkologii Im. Marii Sklodowskiej‑Curie‑Panstwowy Instytut Badawczy in Warsaw is conducting a series of trials focused on Hepatocellular Carcinoma, exploring new combination therapy approaches to improve response rates and survival outcomes.
- Evaluate efficacy of anti‑PD‑1 based combinations
- Assess safety of dual checkpoint blockade
- Compare progression‑free survival across regimens
- Investigate biomarkers predicting treatment benefit
- Explore first‑line therapeutic options for advanced disease
Across 11 trials, 55 investigators are collaborating to bring innovative liver cancer therapies to patients in Europe.
Metastatic Colorectal Cancer Studies
Research at the institute includes targeted investigations of Microsatellite Instability‑High and KRAS mutant metastatic colorectal cancer, testing novel agents and personalized treatment strategies.
- Identify optimal dosing of targeted agents
- Test efficacy of checkpoint inhibitors in MSI‑H disease
- Determine safety of multi‑arm regimens
- Analyze response rates in KRAS‑mutant tumors
- Validate predictive biomarkers for therapy selection
The program emphasizes personalized medicine and collaborates with leading European oncology networks.
Immuno‑oncology Combination Trials
The site is advancing immune checkpoint inhibitor research by evaluating combinations such as relatlimab with nivolumab and triple‑agent regimens that include atezolizumab, bevacizumab, and tiragolumab.
- Compare monotherapy versus combination response
- Measure overall survival benefit of added agents
- Assess tolerability of triple‑agent protocols
- Explore synergy between anti‑PD‑L1 and anti‑CTLA‑4 antibodies
- Monitor immune‑related adverse events across cohorts
These efforts reflect a commitment to expanding immunotherapy options for patients across Europe.
Solid Tumor & Biomarker Research
A broad solid tumor program investigates KRAS mutation driven cancers and other biomarker‑defined subsets, integrating genomic profiling to guide early‑phase studies such as the MK‑1084 trial.
- Investigate novel agents in KRAS‑mutant cancers
- Evaluate response in lung cancer cohorts
- Determine biomarker prevalence across tumor types
- Conduct early‑phase safety assessments of emerging drugs
- Integrate genomic data into trial design for precision therapy
As Poland’s national oncology institute, the center supports a multidisciplinary team of 55 investigators dedicated to cutting‑edge cancer research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 11 therapeutic areas and 15 of 168 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 168 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 25 by active trials.
- 1Merck Sharp & Dohme LLC9active
lock +24 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC39trials
lock +14 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy
lock Showing 1 of 119 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors | Cogent Biosciences Inc. | Phase III | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 168 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 45 | Unknown | 2016-02-02 | 2026-08-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.